TuHURA Biosciences, Inc./NV Logo

TuHURA Biosciences, Inc./NV

Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.

HURA | US

Overview

Corporate Details

ISIN(s):
US49720K1016
LEI:
Country:
United States of America
Address:
10500 UNIVERSITY CENTER DR., 33612 TAMPA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's core mission is to address the challenges of treatment resistance in cancer patients. Its pipeline is built upon distinct technology platforms, including the IMMUNE FX (IFX) innate immune agonist, designed to enhance the efficacy of existing and new cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TuHURA Biosciences, Inc./NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TuHURA Biosciences, Inc./NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TuHURA Biosciences, Inc./NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America CARM
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920

Talk to a Data Expert

Have a question? We'll get back to you promptly.